Security record · archived quarter
ABVX
Abivax S.A. · Healthcare · Biotechnology
5Tracked holders
—Δ holders
1.50MShares held
$19.77MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 83 | +12 | 15.45M | $2.06B | +16 | −3 |
| Q1 2026 | 72 | -1 | 18.00M | $2.00B | +4 | −5 |
| Q4 2025 | 72 | +3 | 22.08M | $2.98B | +3 | — |
| Q3 2025 | 11 | +5 | 9.45M | $802.20M | +5 | — |
| Q2 2025 | 4 | -1 | 2.69M | $20.57M | — | −1 |
| Q1 2025 | 5 | 0 | 2.48M | $15.51M | +1 | −1 |
| Q4 2024 | 5 | -1 | 1.91M | $14.02M | +1 | −2 |
| Q3 2024 | 6 | +1 | 2.23M | $25.72M | +1 | — |
| Q2 2024 | 5 | — | 1.50M | $19.77M | — | — |
Who holds it · Q2 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Adage Capital Partners ✦ | 525.00K | — | $6.94M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Citadel Advisors ✦ | 454.76K | — | $6.01M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Citadel Advisors ✦ | 454.76K | — | $6.01M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Point72 Asset Management ✦ | 423.60K | — | $5.60M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Millennium Management ✦ | 77.60K | — | $1.03M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 14.39K | — | $190,222 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 250 holders, 49.39M shares, $5.28B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2024 ·
Methodology ·
Get this via the API